{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:37:01Z","timestamp":1792089421338,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12325-023-02689-6","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:02:19Z","timestamp":1696615339000},"page":"5399-5414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-Term Outcomes of Eladocagene Exuparvovec Compared with Standard of Care in Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency: A Modelling Study"],"prefix":"10.1007","volume":"40","author":[{"given":"Claire L.","family":"Simons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-9345","authenticated-orcid":false,"given":"Rongrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn J. H. G.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Bergkvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Bennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"issue":"1","key":"2689_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13023-016-0522-z","volume":"12","author":"T Wassenberg","year":"2017","unstructured":"Wassenberg T, Molero-Luis M, Jeltsch K, et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis. 2017;12(1):12.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2689_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymgme.2019.03.009","volume":"127","author":"N Himmelreich","year":"2019","unstructured":"Himmelreich N, Montioli R, Bertoldi M, et al. Aromatic amino acid decarboxylase deficiency: molecular and metabolic basis and therapeutic outlook. Mol Genet Metab. 2019;127(1):12\u201322.","journal-title":"Mol Genet Metab"},{"issue":"10","key":"2689_CR3","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/WNL.42.10.1980","volume":"42","author":"K Hyland","year":"1992","unstructured":"Hyland K, Surtees RA, Rodeck C, Clayton PT. Aromatic l-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology. 1992;42(10):1980\u20138.","journal-title":"Neurology"},{"issue":"40","key":"2689_CR4","first-page":"1","volume":"31","author":"WL Hwu","year":"2017","unstructured":"Hwu WL, Chien YH, Lee NC, Li MH. Natural history of aromatic l-amino acid decarboxylase deficiency in Taiwan. JIMD Rep. 2017;31(40):1\u20136.","journal-title":"JIMD Rep"},{"issue":"134","key":"2689_CR5","doi-asserted-by":"publisher","first-page":"13461","DOI":"10.1126\/scitranslmed.3003640","volume":"4","author":"WL Hwu","year":"2012","unstructured":"Hwu WL, Muramatsu S, Tseng SH, et al. Gene therapy for aromatic l-amino acid decarboxylase deficiency. Sci Transl Med. 2012;4(134):13461.","journal-title":"Sci Transl Med"},{"key":"2689_CR6","first-page":"1","volume":"18","author":"K Buesch","year":"2022","unstructured":"Buesch K, Zhang R, Szczepa\u0144ska K, et al. Burden and severity of disease of aromatic l-amino acid decarboxylase deficiency: a systematic literature review. Curr Med Res Opin. 2022;18:1\u201312.","journal-title":"Curr Med Res Opin"},{"key":"2689_CR7","unstructured":"Whitehead N, Schu M, Erickson SW, Croxford J, Peters M, Hyland K. Estimated prevalence of aromatic l-amino acid decarboxylase (AADC) deficiency in the United States, European Union, and Japan. In: European Society for Gene and Cell Therapy 26th Annual Congress. Lausanne, Switzerland; 2018."},{"issue":"1\u20132","key":"2689_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ymgme.2021.06.010","volume":"134","author":"N Himmelreich","year":"2021","unstructured":"Himmelreich N, Montioli R, Bertoldi M, et al. Corrigendum to \u2018Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook\u2019 [Mol Genet Metab. 2019 May;127(1):12-22]. Mol Genet Metab. 2021;134(1\u20132):216.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"2689_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/jimd.12247","volume":"43","author":"TS Pearson","year":"2020","unstructured":"Pearson TS, Gilbert L, Opladen T, et al. AADC deficiency from infancy to adulthood: symptoms and developmental outcome in an international cohort of 63 patients. J Inherit Metab Dis. 2020;43(5):1121\u201330.","journal-title":"J Inherit Metab Dis"},{"key":"2689_CR10","doi-asserted-by":"publisher","first-page":"FNL63","DOI":"10.2217\/fnl-2022-0012","volume":"17","author":"M Bergkvist","year":"2022","unstructured":"Bergkvist M, Stephens C, Schilling T, et al. Aromatic l-amino acid decarboxylase deficiency: a systematic review. Fut Neurol. 2022;17:FNL63.","journal-title":"Fut Neurol"},{"issue":"2","key":"2689_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","volume":"30","author":"CH Tai","year":"2022","unstructured":"Tai CH, Lee NC, Chien YH, et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol Ther. 2022;30(2):509\u201319.","journal-title":"Mol Ther"},{"issue":"21","key":"2689_CR12","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","volume":"70","author":"JL Eberling","year":"2008","unstructured":"Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;70(21):1980\u20133.","journal-title":"Neurology"},{"issue":"9","key":"2689_CR13","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/mt.2010.135","volume":"18","author":"S Muramatsu","year":"2010","unstructured":"Muramatsu S, Fujimoto K, Kato S, et al. A phase I study of aromatic l-amino acid decarboxylase gene therapy for Parkinson\u2019s disease. Mol Ther. 2010;18(9):1731\u20135.","journal-title":"Mol Ther"},{"issue":"5","key":"2689_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/mds.27993","volume":"35","author":"JG Nutt","year":"2020","unstructured":"Nutt JG, Curtze C, Hiller A, et al. Aromatic l-amino acid decarboxylase gene therapy enhances levodopa response in Parkinson\u2019s disease. Mov Disord. 2020;35(5):851\u20138.","journal-title":"Mov Disord"},{"key":"2689_CR15","unstructured":"EMA. European Medicines Agency. 2022. First therapy to treat rare genetic nervous system disorder AADC deficiency. https:\/\/www.ema.europa.eu\/en\/news\/first-therapy-treat-rare-genetic-nervous-system-disorder-aadc-deficiency. Accessed 25 May 2022."},{"key":"2689_CR16","unstructured":"GOV.UK. Orphan Register. UPSTAZA. 2023. https:\/\/www.gov.uk\/government\/publications\/orphan-registered-medicinal-products\/orphan-register#upstaza. Accessed 22 Mar 2023."},{"issue":"4","key":"2689_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","volume":"1","author":"YH Chien","year":"2017","unstructured":"Chien YH, Lee NC, Tseng SH, et al. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial. Lancet Child Adoles Health. 2017;1(4):265\u201373.","journal-title":"Lancet Child Adoles Health"},{"issue":"1","key":"2689_CR18","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/j.jval.2021.11.512","volume":"25","author":"C Simons","year":"2022","unstructured":"Simons C, Sudhapalli P, Paris JJ, Buesch K, Bennison C. Long term outcomes for patients with aromatic l-amino acid decarboxylase (AADC) deficiency: a modelling study exploring the benefit of gene therapy. Value Health. 2022;25(1):S107\u20138.","journal-title":"Value Health"},{"key":"2689_CR19","doi-asserted-by":"crossref","unstructured":"Simons C, Paris J, Buesch K, Bennison C. Global symptom improvement for patients with aromatic l-amino acid decarboxylase deficiency using individual participant data. International conference of pharmacoepidemiology. 2021.","DOI":"10.1016\/j.jval.2020.08.1747"},{"issue":"Suppl 1","key":"2689_CR20","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.jval.2021.11.369","volume":"25","author":"L Sopena","year":"2022","unstructured":"Sopena L, Simons C, Mumford A, et al. Economic model for a gene therapy in an ultra-rare disease: expert validation of approach and assumptions. Value Health. 2022;25(Suppl 1):S79.","journal-title":"Value Health"},{"issue":"Suppl 2S692","key":"2689_CR21","first-page":"PRO11","volume":"23","author":"C Simons","year":"2020","unstructured":"Simons C, Sudhapalli P, Bennison C, Buesch K. Estimating the long-term effects of therapy for patients with aromatic l-amino acid decarboxylase deficiency (AADC-D) using individual participant data. Value Health. 2020;23(Suppl 2S692):PRO11.","journal-title":"Value Health"},{"key":"2689_CR22","unstructured":"NICE. Guide to the methods of technology appraisal 2013. 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword."},{"issue":"Suppl 2S691","key":"2689_CR23","first-page":"PRO10","volume":"23","author":"P Sudhapalli","year":"2020","unstructured":"Sudhapalli P, Bianco M, Simons C, Bennison C, Buesch K. Identifying appropriate proxy diseases for estimating long-term survival and impact on health-related quality of life of patients with aromatic l-amino acid decarboxylase deficiency (AADC-D). Value Health. 2020;23(Suppl 2S691):PRO10.","journal-title":"Value Health"},{"issue":"11","key":"2689_CR24","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/dmcn.12519","volume":"56","author":"JC Brooks","year":"2014","unstructured":"Brooks JC, Strauss DJ, Shavelle RM, Tran LM, Rosenbloom L, Wu YW. Recent trends in cerebral palsy survival. Part II: individual survival prognosis. Dev Med Child Neurol. 2014;56(11):1065\u201371.","journal-title":"Dev Med Child Neurol"},{"issue":"8","key":"2689_CR25","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1080\/03007995.2021.1932449","volume":"37","author":"K Williams","year":"2021","unstructured":"Williams K, Skrobanski H, Werner C, O\u2019Neill S, Buesch K, Acaster S. Symptoms and impact of aromatic l-amino acid decarboxylase (AADC) deficiency: a qualitative study and the development of a patient-centred conceptual model. Curr Med Res Opin. 2021;37(8):1353\u201361.","journal-title":"Curr Med Res Opin"},{"key":"2689_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/PROM.S306228","volume":"12","author":"AB Smith","year":"2021","unstructured":"Smith AB, Hanbury A, Buesch K. Eliciting health state utilities for aromatic l-amino acid decarboxylase (AADC) deficiency: a UK vignette study. Patient Relat Outcome Meas. 2021;12:237\u201346.","journal-title":"Patient Relat Outcome Meas"},{"issue":"12","key":"2689_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PROM.S278258","volume":"7","author":"A Hanbury","year":"2021","unstructured":"Hanbury A, Smith AB, Buesch K. Deriving vignettes for the rare disease AADC deficiency using parent, caregiver and clinician interviews to evaluate the impact on health-related quality of life. Patient Relat Outcome Meas. 2021;7(12):1\u201312.","journal-title":"Patient Relat Outcome Meas"},{"issue":"10","key":"2689_CR28","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1080\/03007995.2021.1955668","volume":"37","author":"H Skrobanski","year":"2021","unstructured":"Skrobanski H, Williams K, Werner C, O\u2019Neill S, Buesch K, Acaster S. The impact of caring for an individual with aromatic l-amino acid decarboxylase (AADC) deficiency: a qualitative study and the development of a conceptual model. Curr Med Res Opin. 2021;37(10):1821\u20138.","journal-title":"Curr Med Res Opin"},{"key":"2689_CR29","unstructured":"National Institute of Health and Care Excellence. Risdiplam for treating spinal muscular atrophy in children and adults [ID1631] (Committee papers). NICE. https:\/\/www.nice.org.uk\/guidance\/ta755\/documents\/committee-papers-3. Accessed 7 May 2020."},{"issue":"1","key":"2689_CR30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/1472-6963-13-346","volume":"13","author":"S Acaster","year":"2013","unstructured":"Acaster S, Perard R, Chauhan D, Lloyd AJ. A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis. BMC Health Serv Res. 2013;13(1):346.","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"2689_CR31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","volume":"26","author":"R Gani","year":"2008","unstructured":"Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26(7):617\u201327.","journal-title":"Pharmacoeconomics"},{"key":"2689_CR32","unstructured":"PTC Therapeutics. Eladocagene exuparvovec: integrated summary of safety. Data on file."},{"key":"2689_CR33","first-page":"1","volume":"14","author":"S Saberian","year":"2022","unstructured":"Saberian S, Rowan P, Hammes F, et al. Burden of illness of aromatic l-amino acid decarboxylase deficiency: a survey of physicians in southern Europe. Curr Med Res Opin. 2022;14:1\u201333.","journal-title":"Curr Med Res Opin"},{"key":"2689_CR34","unstructured":"NHS. National Schedule of Reference Costs 2020\/21. 2022. https:\/\/improvement.nhs.uk\/resources\/national-cost-collection\/. Accessed 1 Nov 2022."},{"key":"2689_CR35","unstructured":"Curtis L. Unit costs of health and social care. PSSRU."},{"issue":"5","key":"2689_CR36","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. ISPOR-SMDM modeling good research practices task force. Modeling good research practices\u2013overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Mak. 2012;32(5):667\u201377.","journal-title":"Med Decis Mak"},{"issue":"2","key":"2689_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","volume":"18","author":"SD Ramsey","year":"2015","unstructured":"Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161\u201372.","journal-title":"Value Health"},{"issue":"1","key":"2689_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12883-019-1343-1","volume":"19","author":"E Blair","year":"2019","unstructured":"Blair E, Langdon K, McIntyre S, Lawrence D, Watson L. Survival and mortality in cerebral palsy: observations to the sixth decade from a data linkage study of a total population register and National Death Index. BMC Neurol. 2019;19(1):111.","journal-title":"BMC Neurol"},{"issue":"3","key":"2689_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1741-3729.2010.00601.x","volume":"59","author":"J Song","year":"2010","unstructured":"Song J, Floyd FJ, Seltzer MM, Greenberg JS, Hong J. Long-term effects of child death on parents\u2019 health related quality of life: a dyadic analysis. Fam Relat. 2010;59(3):269\u201382.","journal-title":"Fam Relat"},{"issue":"Suppl 2","key":"2689_CR40","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1016\/j.jval.2019.04.1238","volume":"22","author":"J Chambers","year":"2019","unstructured":"Chambers J, Silver MC, Lin PJ, et al. Cell and gene therapies are associated with substantially larger quality-adjusted life year gains than conventional drugs and biologics. Value Health. 2019;22(Suppl 2):S263.","journal-title":"Value Health"},{"issue":"7","key":"2689_CR41","doi-asserted-by":"publisher","first-page":"A419","DOI":"10.1016\/j.jval.2014.08.1026","volume":"17","author":"JD Chambers","year":"2014","unstructured":"Chambers JD, Thorat T, Chenoweth M, Pyo J, Neumann PJ. Do specialty drugs offer greater value for money than traditional drugs? Value Health. 2014;17(7):A419\u201320.","journal-title":"Value Health"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02689-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:10:28Z","timestamp":1698405028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02689-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2689"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02689-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]},"assertion":[{"value":"29 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors Claire L Simons, Martijn JHG Simons, and Craig Bennison acted as consultants to PTC Therapeutics through their employment with OPEN Health Group and declare they have no personal, commercial, academic, or financial conflicts of interest. Rongrong Zhang and Mats Bergkvist are employees of PTC Therapeutics. Wuh-Liang Hwu participated as an advisory board member, received consulting fees, and was a speaker for PTC Therapeutics, BioMarin, and Sanofi. He was a grant recipient for PTC Therapeutics and BioMarin and a research investigator for PTC Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This modelling study used de-identified secondary data, and therefore did not require ethical approval or individual patient consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}